


RealRate

PHARMACEUTICAL 2020

Catalent Inc. Rank 4 of 362





PHARMACEUTICAL 2020



Catalent Inc. Rank 4 of 362

The relative strengths and weaknesses of Catalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Catalent Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 454% points. The greatest weakness of Catalent Inc. is the variable Intangible Assets, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is 396%, being 699% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,395,800
Cost of Goods Sold	0
Intangible Assets	3,151,700
Liabilities, Current	670,700
Liabilities, Non-Current	0
Other Assets	99,800
Other Compr. Net Income	-51,000
Other Expenses	14,100
Other Liabilities	0
Other Net Income	-118,700
Property and Equipment	1,536,700
Research and Development	0
Revenues	2,518,000
Selling, General and Administrative Expense	512,000

Output Variable	Value in 1000 USD
Assets	6,184,000
Liabilities	670,700
Expenses	526,100
Stockholders Equity	5,513,300
Net Income	1,873,200
Comprehensive Net Income	1,847,700
Economic Capital Ratio	396%